贝瑞基因(000710) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit in the range of -25,000 to -17,000 thousand yuan for the fiscal year 2025, compared to a net profit of -19,242.85 thousand yuan in the previous year[5]. - The net profit excluding non-recurring gains and losses is projected to be between -24,500 and -16,500 thousand yuan, compared to -19,219.19 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.71 and -0.48 yuan, compared to -0.54 yuan in the previous year[5]. - Non-recurring gains and losses are estimated to impact net profit by approximately 5,000 thousand yuan, compared to 240 thousand yuan in the same period last year[4]. - The company has conducted a comprehensive review and impairment testing of various assets, which has also affected the net profit for the reporting period[4]. - Investors are advised to note that the financial data is based on preliminary calculations and the final figures will be disclosed in the 2025 annual report[6]. Revenue and Market Factors - The decline in revenue is attributed to factors such as a decrease in birth rates, while operating cash flow remains stable[4]. - The newborn genetic screening business is progressing as expected, which is anticipated to positively impact the company's business layout in reproductive health[4]. Research and Development - The company has increased its R&D investment, which has impacted the current net profit due to high phase expenditures[4]. - The integration of genetic testing technology with artificial intelligence algorithms is expected to drive innovation in precision medicine and generate revenue[4].